Skip to content

Zymeworks ZYME Change in Deferred Revenue

Change in Deferred Revenue at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$8.03M-160%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$2.19M-123%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$16.24M-139%
TG Therapeutics logo
TG TherapeuticsTGTX
-$5.99M-4,377%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$5.2M+528%
Innoviva, Inc. logo
Innoviva, Inc.INVA
-$593K-378%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's change in deferred revenue?
Zymeworks (ZYME) reported change in deferred revenue of -$340K in Q1 2026.
How has Zymeworks's change in deferred revenue changed year-over-year?
Zymeworks's change in deferred revenue increased by 83.8% year-over-year, from -$2.09M to -$340K.
What does change in deferred revenue mean?
Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.